Blocking the CD47-SIRPα axis significantly enhances macrophage-mediated tumor phagocytosis, which has been shown to be effective in EOC models, and several anti-CD47 monoclonal antibodies (e.g., magrolimab) are in clinical trials (107). Here, CD47 is linked to neoplasm.